aTyr Pharma, Inc.
ATYR
$0.53
-$0.03-5.75%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/12/2026
-
MarketBeat
6/26/2026
-
Globe Newswire
6/23/2026
-
Globe Newswire
6/9/2026
-
Simply Wall St
6/8/2026
-
TipRanks
6/4/2026
-
TipRanks Financial Blog
5/19/2026
-
TipRanks Financial Blog
5/15/2026
-
Globe Newswire
5/14/2026
-
SeekingAlpha
5/13/2026
-
Globe Newswire
5/12/2026
-
SeekingAlpha
5/12/2026
-
Seeking Alpha: Transcripts
5/12/2026
-
TipRanks Financial Blog
5/12/2026
-
TipRanks Financial Blog
5/12/2026
-
MarketBeat
5/11/2026
-
TipRanks Financial Blog
5/11/2026
-
Globe Newswire
5/10/2026
-
The Cerbat Gem
5/9/2026
-
MarketBeat
5/4/2026
-
The Cerbat Gem
4/29/2026
-
MarketBeat
4/19/2026
-
MarketBeat
4/17/2026
-
Simply Wall St
3/25/2026
-
MarketBeat
3/15/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, May 15, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
858 731 8389
Address
10240 Sorrento Valley Road
San Diego, CA 92121
San Diego, CA 92121
Country
Year Founded
Business Description
Sector
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis...
more